Rethinking Obesity: Novo Nordisk's Latest Initiative Urges Singaporeans to Treat, Not Blame
'Beyond the Scale' focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based care.
SINGAPORE - Media OutReach Newswire - 27 June 2025 - Imagine a chronic disease affecting more than 600,000 people 1-3 in Singapore — yet often misunderstood, overlooked, or surrounded by stigma. This is the reality of obesity today. For many, outdated perceptions and delays in care have created barriers to support and treatment. Today, a new initiative is calling for a shift — to change how we think, talk about, and respond to obesity, through a lens of science, empathy, and early intervention.
Breaking the Myths: A Public Health Reframe
"Just eat less." "Try harder." "It's a lifestyle choice." These are more than just phrases — they reflect a deeper misunderstanding of obesity. Today, a bold new initiative, seeks to challenge those misconceptions and open the door to a more compassionate, evidence-based conversation. "Beyond the Scale" launches across Singapore with a clear and urgent call to focus on obesity as not a failure of willpower, but as a complex, chronic disease. The initiative invites the public to go beyond — beyond stigma, beyond myths, beyond labels — and recognise obesity for what science confirms it to be: a multifactorial health condition that deserves understanding, early intervention, and clinical care.
Led by global healthcare company Novo Nordisk in collaboration with local healthcare professionals and patient advocates, "Beyond the Scale" is a disease awareness initiative aimed at driving a shift in how individuals, communities, and healthcare providers approach obesity management.
"We believe it's time to shift from blame to understanding," said General Manager, Mr Vincent Siow of Novo Nordisk Singapore. "Obesity affects 1 out of 9 people in Singapore 4, yet it's still too often seen as a matter of willpower. The reality is that obesity is a complex, chronic disease driven by biology, environment, and unequal access to care. 1,5 It's time we treat it with the seriousness it deserves — and we are proud to lead that conversation and drive meaningful change through the "Beyond the Scale" initiative.
Why This Matters Now
The 2021–2022 National Population Health Survey reveals the highest obesity rate (15%) among adults aged 40 to 49, while 43.3% of residents aged 18 to 74 had abdominal obesity, which increases with age and peaks between 50 to 74 years. 6 This is compounded by the fact that perceptions persist about obesity being a personal failing, discouraging individuals from seeking help, delaying diagnosis, and compounding the health burden on families and the healthcare system.
Obesity significantly increases the risk of cardiovascular disease (CVD), type 2 diabetes, and chronic kidney disease (CKD) 7, all of which already place a growing strain on Singapore's healthcare infrastructure. The economic impact is substantial: in 2019, metabolic-risk related diseases, including obesity, diabetes, hypertension, CKD, and cardiovascular conditions, cost Singapore S$2.20 billion. 8 Of this, S$642 million were healthcare expenditures 8, and excess weight alone accounted for an estimated S$261 million in annual medical and absenteeism costs. 9 Without decisive public health action, these obesity-related comorbidities are poised to escalate into a major societal and economic burden.
"This is not just a personal issue — it's a public health priority," said Dr Ben Ng, Arden Diabetes & Endocrine Clinic. "We know obesity changes how the body regulates appetite, energy storage, and metabolism. It's a disease, not a choice. Science supports this — and our response should reflect it."
The Science Behind the Message
Obesity is not simply about calories in and out. Research confirms it involves neuroendocrine (hormonal), genetic, and psychosocial factors, making it both preventable and treatable 10.
Studies show that in Singapore, weight stigma is often driven by the belief that obesity is a personal failing, lack of willpower, or lifestyle choice leading to delayed treatment, reduced care-seeking, and poorer health outcomes, particularly in managing chronic conditions such as cardiovascular and kidney disease. 11
Beyond Labels, Toward Lasting Change
"Beyond the Scale" is more than a slogan — it is a call to treat obesity as the complex, chronic disease that it is. To move away from blame, appearance-based judgments, and oversimplified narratives, toward empathy, science, and sustained health. It is an urgent appeal to rethink, retrain, and rehumanise the way we support individuals living with obesity.
"The earlier we intervene, the better the outcomes," said Dr. Ng."Obesity is not a character flaw. It's a disease. And it's time we responded with the same respect, science, and care we give every other chronic condition."
"Beyond the Scale" aims to:
Raise awareness of obesity as a chronic, multifactorial disease.
Reduce stigma and myths that hinder early care.
Encourage timely, evidence-based conversations with healthcare professionals.
Promote empathy and science within the medical community.
Support patients with tools to take charge of their health.
Singaporeans can participate by:
Visiting [ www.truthaboutweight.sg ] for factual resources, use a BMI measurement tool, and locate a nearest weight management healthcare professional.
Starting honest conversations with GPs, nurses, and pharmacists.
Sharing content to help dismantle myths and support loved ones on their health journeys.
1. Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508.
2. World Obesity. Retrieved from https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity
3. World Obesity. Retrieved from https://data.worldobesity.org/country/singapore-192/
4. Lee, Y. V., & Tan, N. C. (2014). Obesity in Singapore: An update. The Singapore Family Physician, 40(2), 11–16. https://cfps.org.sg/publications/the-singapore-family-physician/article/71_pdf
5. World Health Organization. (2024). Obesity and overweight. WHO.https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight As accessed on 22nd May 2025.
6. Ministry of Health, Singapore. (2022). National Population Health Survey 2022 Report. https://isomer-user-content.by.gov.sg/3/28c3b8f9-9216-46be-8fc9-b614098666a9/nphs-2022-survey-report_final.pdf
7. Cohen JB, Cohen DL. Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome. Curr Hypertens Rep. 2015 May;17(5):34. doi: 10.1007/s11906-015-0544-2. PMID: 25833456; PMCID: PMC4427189.
8. Tan, V., Lim, J., Akksilp, K. et al. The societal cost of modifiable risk factors in Singapore. BMC Public Health 23, 1285 (2023). https://doi.org/10.1186/s12889-023-16198-2 (2.2 Billion)
9. Junxing C, Huynh VA, Lamoureux E, Tham KW, Finkelstein EA. Economic burden of excess weight among older adults in Singapore: a cross-sectional study. BMJ Open. 2022 Sep 16;12(9):e064357. doi: 10.1136/bmjopen-2022-064357. PMID: 36113947; PMCID: PMC9486358.
10. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May 10. PMID: 28489290.
11. Goff AJ, Lee Y, Tham KW. Weight bias and stigma in healthcare professionals: a narrative review with a Singapore lens. Singapore Med J. 2023 Mar;64(3):155-162. doi: 10.4103/singaporemedj.SMJ-2022-229. PMID: 36876621; PMCID: PMC10071861.
Hashtag: #NovoNordisk
The issuer is solely responsible for the content of this announcement.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees.
"Beyond the Scale" campaign builds on Novo Nordisk's long-standing commitment to tackling chronic diseases. With over 100 years of experience advancing care for diabetes and more than 25 years of focused obesity research, Novo Nordisk is pioneering the medical management of obesity and the science of the GLP-1 hormone — a naturally occurring signal that regulates appetite and plays a key role in achieving sustained weight loss.
As part of its mission to drive long-term health outcomes, Novo Nordisk is also investing in scalable prevention efforts. Through the Cities for Better Health initiative — a global public-private partnership spanning over 50 cities — Novo Nordisk is working to reduce chronic disease risk in vulnerable urban communities. Its latest programme, the Childhood Obesity Prevention Initiative (COPI), delivers targeted interventions to promote healthier diets and physical activity among children aged 6–13 in underserved areas.
In Singapore and beyond, these initiatives reinforce Novo Nordisk's holistic approach: treating obesity with medicine and empathy today, while building healthier environments for the next generation.
For more information, visit novonordisk.sg.
Novo Nordisk
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
an hour ago
- Zawya
World Bank Approves Health Resilience Project to Protect Lives and Strengthen Emergency Response in Mozambique
The World Bank has approved the Mozambique Health Emergency Preparedness, Response and Resilience Project, an initiative to strengthen the health system's ability to deliver essential services consistently and equitably. The project targets underserved and climate-vulnerable areas by investing in human resources, infrastructure, and systems that ensure continuity of care during emergencies. This project is part of a regional p rogram to strengthen health security across Eastern and Southern Africa. Mozambique faces frequent floods, cyclones, disease outbreaks, and other emergencies that disrupt health services and put lives at risk. Many communities lack sufficient and trained health workers, access to essential medicines, and the tools to detect and respond quickly to crises. The project seeks to address these gaps by: Strengthening the health workforce capacity, particularly in high-risk areas, by improving recruitment, training, and retention systems; Improving pharmaceutical supply chains by supporting the regulatory agency in bringing more transparency and speed to procurement processes, lowering and standardizing prices of health commodities to ensure access to medicines, particularly during crises; and Enhancing disease surveillance and laboratory capacity to improve early warning and response systems to quickly detect and respond to health emergencies like cholera outbreaks or heatwaves. The project also supports the development of climate-adaptive infrastructure and emergency preparedness plans, recognizing the growing health risks posed by climate change. ' Mozambique is already experiencing the health impacts of shocks and emergencies,' noted Luc Lecuit, World Bank Acting Division Director in Mozambique. 'The program supports the government's efforts to strengthen core health service delivery by investing in preparedness and resilience, ensuring services remain operational during floods, storms, and epidemics.' Financed through a $201 million grant from the International Development Association (IDA)*, the initiative will be implemented over five years, concluding in September 2030. 'By prioritizing practical investments in the foundational pillars of the health sector, the Government of Mozambique is driving greater efficiency across the system and strengthening its emergency response capacity to protect lives,' said João Pires, World Bank Senior Health Specialist and Task Team Leader. 'These efforts are paving the way for bold reforms to ensure the health system remains resilient and responsive, even under pressure.' In parallel, the World Bank, together with other development partners, is increasing its support to the Mozambique health sector through a $63.7 million top-up to the ongoing District and Community Health Services Revitalization Project. This additional financing—comprising $8.7 million from IDA, $5 million from the Global Financing Facility, and $50 million from a multi-donor trust fund supported by Canada, the United Kingdom, and Ireland—will expand the project's impact across the most vulnerable 63 districts of Mozambique. The operation focuses on improving access to quality primary health care, particularly for women, children, and adolescents, and strengthening service delivery at the district and community levels. Both projects align with the forthcoming Mozambique's Health Sector Strategic Plan (PESS, 2025-2034) (PESS 2020–2024) and the National Adaptation Plan (2023), and complement regional efforts to strengthen health security across Eastern and Southern Africa. Distributed by APO Group on behalf of The World Bank Group.
Arabian Post
2 hours ago
- Arabian Post
Tanoto Foundation Backs Landmark Research to Unlock the Code of Asian Prevalent Diseases
Understanding Asian Cancers and Diabetes Through an Asian Lens SINGAPORE – Media OutReach Newswire – 27 June 2025 – Tanoto Foundation today announced the funding of two transformative, Singapore-based medical research projects focused on diseases that disproportionately affect Asian populations: prevalent and aggressive cancers, and young-onset Type 2 diabetes. The multi-year initiatives aim to generate data-driven insights that can accelerate diagnosis, improve patient outcomes, and guide public health policy. NCCS and SGH secure research funding from Tanoto Foundation for projects tackling Asian-prevalent cancers and young-onset diabetes to drive breakthroughs in regional health Despite global strides in medicine, Asia continues to face rising rates of cancer and diabetes – diseases that are biologically and clinically distinct in Asian populations but remain under-researched due to a lack of region-specific data. The two research projects, from National Cancer Centre Singapore and Singapore General Hospital, will focus on filling these gaps through deep genomic studies and innovative risk-prediction models. ADVERTISEMENT Imelda Tanoto, Member of the Board of Trustees, Tanoto Foundation said: 'Singapore is well-positioned to lead in medical science. It has strong research institutions and a population that reflects the diversity of Asia. By supporting researchers here who are focused on health issues that affect Asians, we hope to help drive discoveries that make a real difference to people's lives — both in Singapore and across the region.' Tackling Asian-Prevalent Cancers Led by Dr Jason Chan, Medical Oncologist, National Cancer Centre Singapore, the research will investigate four types of cancers with high prevalence and poor outcomes in Asia: Breast Cancer in Asian Women, marked by earlier onset and biological differences compared to Western populations T/NK-Cell Lymphomas, an aggressive blood cancer dominant in East Asians with limited treatment options Bile Duct Cancer (Cholangiocarcinoma), increasingly linked to environmental exposures specific to Asia Rare Asian Cancers, collectively neglected but accounting for up to 25% of all cases in the region These cancers are devastating but remain poorly understood because most research has focused on Western populations,' said Dr Chan. 'By decoding their molecular and genomic landscapes in Asian patients, we want to uncover new diagnostic and therapeutic opportunities to benefit patients.' A key feature of the project is its open-access commitment: anonymised data will be freely available to the broader research community to accelerate further discovery and collaboration. Unmasking Diabetes Risk in Young Singaporeans The second research project, led by Dr Daphne Gardner, Endocrinologist, Singapore General Hospital, will address the rising incidence of Type 2 diabetes in young adults, particularly prevalent in Singapore, where 1 in 5 young adults have prediabetes or diabetes, despite being of normal weight. ADVERTISEMENT Unlike traditional assessments that rely heavily on BMI and family history, this project will develop a next-generation risk prediction tool by incorporating non-traditional indicators such as body fat distribution, continuous glucose monitoring, and health-seeking behaviour. 'Many young Asians with diabetes don't fit the usual risk profile. They're lean, active, and often overlooked by current screening models,' said Dr Gardner. 'We want to change that by identifying new risk signals and developing tools that are tailored to Singapore's population and beyond.' Findings from the study aim to inform national diabetes screening guidelines and lead to earlier interventions that can curb long-term complications. Singapore as a Hub for Medical Research Advancement In addition to previously supported research projects, these two initiatives reflect a growing recognition of Singapore's role in advancing precision medicine for Asian populations, driven by strong clinical infrastructure, genomic capabilities, and public-private partnerships. Imelda Tanoto added: 'We believe precision health can change how we treat and prevent diseases. We're supporting researchers who are not only breaking new ground, but also making sure their work reaches people and communities across Asia. This is something deeply personal to us — it's about improving lives in a way that's inclusive, meaningful, and lasting.' This announcement marks a key milestone in Tanoto Foundation's continuing effort to improve the quality of healthcare and health standards, leading to longer and better healthspans. Hashtag: #TanotoFoundation The issuer is solely responsible for the content of this announcement. About Tanoto Foundation At Tanoto Foundation, we unlock human potential, help communities thrive, and create lasting impact. Founded in 1981 by Sukanto Tanoto and Tinah Bingei Tanoto, we are an independent family foundation that believes in providing every person with the opportunity to realize his or her full potential. To do so, we catalyse systems change in education and healthcare. Our approach is impact-first, collaborative, and evidence-based. We invest for the long term and strive to develop leaders who can drive sustained, positive outcomes. More information is available at
Zawya
2 hours ago
- Zawya
Tanoto Foundation Backs Landmark Research to Unlock the Code of Asian Prevalent Diseases
Understanding Asian Cancers and Diabetes Through an Asian Lens SINGAPORE - Media OutReach Newswire - 27 June 2025 - Tanoto Foundation today announced the funding of two transformative, Singapore-based medical research projects focused on diseases that disproportionately affect Asian populations: prevalent and aggressive cancers, and young-onset Type 2 diabetes. The multi-year initiatives aim to generate data-driven insights that can accelerate diagnosis, improve patient outcomes, and guide public health policy. Despite global strides in medicine, Asia continues to face rising rates of cancer and diabetes – diseases that are biologically and clinically distinct in Asian populations but remain under-researched due to a lack of region-specific data. The two research projects, from National Cancer Centre Singapore and Singapore General Hospital, will focus on filling these gaps through deep genomic studies and innovative risk-prediction models. Imelda Tanoto, Member of the Board of Trustees, Tanoto Foundation said: "Singapore is well-positioned to lead in medical science. It has strong research institutions and a population that reflects the diversity of Asia. By supporting researchers here who are focused on health issues that affect Asians, we hope to help drive discoveries that make a real difference to people's lives — both in Singapore and across the region." Tackling Asian-Prevalent Cancers Led by Dr Jason Chan, Medical Oncologist, National Cancer Centre Singapore, the research will investigate four types of cancers with high prevalence and poor outcomes in Asia: Breast Cancer in Asian Women, marked by earlier onset and biological differences compared to Western populations T/NK-Cell Lymphomas, an aggressive blood cancer dominant in East Asians with limited treatment options Bile Duct Cancer (Cholangiocarcinoma), increasingly linked to environmental exposures specific to Asia Rare Asian Cancers, collectively neglected but accounting for up to 25% of all cases in the region These cancers are devastating but remain poorly understood because most research has focused on Western populations," said Dr Chan. "By decoding their molecular and genomic landscapes in Asian patients, we want to uncover new diagnostic and therapeutic opportunities to benefit patients." A key feature of the project is its open-access commitment: anonymised data will be freely available to the broader research community to accelerate further discovery and collaboration. Unmasking Diabetes Risk in Young Singaporeans The second research project, led by Dr Daphne Gardner, Endocrinologist, Singapore General Hospital, will address the rising incidence of Type 2 diabetes in young adults, particularly prevalent in Singapore, where 1 in 5 young adults have prediabetes or diabetes, despite being of normal weight. Unlike traditional assessments that rely heavily on BMI and family history, this project will develop a next-generation risk prediction tool by incorporating non-traditional indicators such as body fat distribution, continuous glucose monitoring, and health-seeking behaviour. "Many young Asians with diabetes don't fit the usual risk profile. They're lean, active, and often overlooked by current screening models," said Dr Gardner. "We want to change that by identifying new risk signals and developing tools that are tailored to Singapore's population and beyond." Findings from the study aim to inform national diabetes screening guidelines and lead to earlier interventions that can curb long-term complications. Singapore as a Hub for Medical Research Advancement In addition to previously supported research projects, these two initiatives reflect a growing recognition of Singapore's role in advancing precision medicine for Asian populations, driven by strong clinical infrastructure, genomic capabilities, and public-private partnerships. Imelda Tanoto added: "We believe precision health can change how we treat and prevent diseases. We're supporting researchers who are not only breaking new ground, but also making sure their work reaches people and communities across Asia. This is something deeply personal to us — it's about improving lives in a way that's inclusive, meaningful, and lasting." This announcement marks a key milestone in Tanoto Foundation's continuing effort to improve the quality of healthcare and health standards, leading to longer and better healthspans. Hashtag: #TanotoFoundation The issuer is solely responsible for the content of this announcement. About Tanoto Foundation At Tanoto Foundation, we unlock human potential, help communities thrive, and create lasting impact. Founded in 1981 by Sukanto Tanoto and Tinah Bingei Tanoto, we are an independent family foundation that believes in providing every person with the opportunity to realize his or her full potential. To do so, we catalyse systems change in education and healthcare. Our approach is impact-first, collaborative, and evidence-based. We invest for the long term and strive to develop leaders who can drive sustained, positive outcomes. More information is available at Tanoto Foundation
